Department of Psychiatry & Behavioral Sciences, University of Minnesota, Minneapolis, MN, USA.
Neuropsychopharmacology. 2024 Jan;49(1):138-149. doi: 10.1038/s41386-023-01643-y. Epub 2023 Jul 6.
Deep brain stimulation (DBS) is an invasive approach to precise modulation of psychiatrically relevant circuits. Although it has impressive results in open-label psychiatric trials, DBS has also struggled to scale to and pass through multi-center randomized trials. This contrasts with Parkinson disease, where DBS is an established therapy treating thousands of patients annually. The core difference between these clinical applications is the difficulty of proving target engagement, and of leveraging the wide range of possible settings (parameters) that can be programmed in a given patient's DBS. In Parkinson's, patients' symptoms change rapidly and visibly when the stimulator is tuned to the correct parameters. In psychiatry, those same changes take days to weeks, limiting a clinician's ability to explore parameter space and identify patient-specific optimal settings. I review new approaches to psychiatric target engagement, with an emphasis on major depressive disorder (MDD). Specifically, I argue that better engagement may come by focusing on the root causes of psychiatric illness: dysfunction in specific, measurable cognitive functions and in the connectivity and synchrony of distributed brain circuits. I overview recent progress in both those domains, and how it may relate to other technologies discussed in companion articles in this issue.
深部脑刺激(DBS)是一种精确调节精神相关回路的侵入性方法。尽管它在开放性精神科试验中取得了令人印象深刻的结果,但 DBS 也难以通过多中心随机试验进行扩展。这与帕金森病形成鲜明对比,DBS 是一种成熟的治疗方法,每年为数以千计的患者提供治疗。这些临床应用之间的核心区别在于证明靶点结合的难度,以及利用在给定患者的 DBS 中可以编程的广泛可能设置(参数)的难度。在帕金森病中,当刺激器调谐到正确的参数时,患者的症状会迅速而明显地变化。在精神病学中,这些相同的变化需要数天到数周的时间,这限制了临床医生探索参数空间和确定患者特定最佳设置的能力。我回顾了用于精神科目标评估的新方法,重点是重性抑郁障碍(MDD)。具体来说,我认为更好的参与可能来自于关注精神疾病的根本原因:特定的、可测量的认知功能以及分布式大脑回路的连接和同步功能障碍。我概述了这两个领域的最新进展,以及它们可能与本期中其他文章讨论的其他技术相关。